There have been many N2 operational changes over the past several months. In February, N2 co-founder Karen Arts retired from her many roles with N2, including Board member, SOP Committee chair, and N2 operations support. Steven Sundquist from Canadian Cancer Clinical Trials Network (3CTN) replaced Karen as the Chair of the SOP Committee.
Stephen has over 25 years of experience in clinical trials and health programs’ leadership. His clinical research expertise includes roles in pharma, CRO and academic settings involving the conduct of Phase 1-3b drug, biologic, and device trials across a wide range of therapeutic areas. In his role as Executive Director for the Canadian Cancer Clinical Trials Network (3CTN), Stephen is responsible for leading initiatives designed to improve equitable trial access, patient accrual as well as the efficient, high-quality conduct of academic cancer clinical trials led by the nearly 60 Network Cancer Centres across Canada.
